Multilocus sequence typing of strains from the Cryptococcus gattii species complex from different continents.
Cryptococcus gattii
antifungals susceptibility testing
complex species
molecular diversity
molecular epidemiology
muli-locus sequence typing
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
27
10
2021
received:
09
09
2021
accepted:
28
10
2021
pubmed:
3
11
2021
medline:
7
1
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Cryptococcus neoformans and Cryptococcus gattii species complexes are pathogens causing cryptococcal meningitis, a fungal infection that leads to death unless treated. Worldwide, it is estimated to kill over 180,000 individuals annually. We aim to investigate the molecular diversity of C. gattii isolates from strains isolated from 1995 to the present day from different continents. In this study, we analysed the molecular diversity by MLST and antifungal susceptibility by using the broth microdilution method according to the CLSI M27-A4 protocol of a total of 26 strains from Cryptococcus gattii species complex from both clinical and environmental sources. Genotyping showed that most of the strains (17/26; 65.4%) belonged to serotype B and were distributed between three genotypes: VGI (13/17; 76.5%), VGII (3/17; 17.6%) and VGVI (1/17; 5.9%). The serotype C strains (9/26; 34.6%) were distributed between the VGIII (1/9; 11.1%) and VGIV (8/9; 88.9%) genotypes. The 26 strains belonged to 17 different MLST subtypes, and we highlight four new MLST genotypes (ST553, 554, 555 and 556). The two environmental strains were identified as serotype B and genotype VGI, but were of ST 51 and 154. All isolates have wild-type MIC of fluconazole and flucytosine. Regarding amphotericin B, five VGI strains showed MICs to AMB equal to 1 µg/ml, and according to the ECV for these genotypes, they were considered non-wild-type strains. The current study reveals the genetic diversity and new sequence types among strains from the C. gattii complex species.
Sections du résumé
BACKGROUND
BACKGROUND
Cryptococcus neoformans and Cryptococcus gattii species complexes are pathogens causing cryptococcal meningitis, a fungal infection that leads to death unless treated. Worldwide, it is estimated to kill over 180,000 individuals annually.
OBJECTIVES
OBJECTIVE
We aim to investigate the molecular diversity of C. gattii isolates from strains isolated from 1995 to the present day from different continents.
METHOD
METHODS
In this study, we analysed the molecular diversity by MLST and antifungal susceptibility by using the broth microdilution method according to the CLSI M27-A4 protocol of a total of 26 strains from Cryptococcus gattii species complex from both clinical and environmental sources.
RESULTS
RESULTS
Genotyping showed that most of the strains (17/26; 65.4%) belonged to serotype B and were distributed between three genotypes: VGI (13/17; 76.5%), VGII (3/17; 17.6%) and VGVI (1/17; 5.9%). The serotype C strains (9/26; 34.6%) were distributed between the VGIII (1/9; 11.1%) and VGIV (8/9; 88.9%) genotypes. The 26 strains belonged to 17 different MLST subtypes, and we highlight four new MLST genotypes (ST553, 554, 555 and 556). The two environmental strains were identified as serotype B and genotype VGI, but were of ST 51 and 154. All isolates have wild-type MIC of fluconazole and flucytosine. Regarding amphotericin B, five VGI strains showed MICs to AMB equal to 1 µg/ml, and according to the ECV for these genotypes, they were considered non-wild-type strains.
CONCLUSIONS
CONCLUSIONS
The current study reveals the genetic diversity and new sequence types among strains from the C. gattii complex species.
Substances chimiques
Fluconazole
8VZV102JFY
Flucytosine
D83282DT06
Banques de données
RefSeq
['MW300350', 'MW300416', 'MN431744', 'MN431749', 'MN431753', 'MN431758']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-96Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881.
Chen SC, Meyer W, Sorrell TC Cryptococcus gattii infections. Clin Microbiol Rev. 2014;27(4):980-1024.
Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015;78:16-48.
Kwon-Chung KJ, Fraser JA, Doering TL, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014;4(7):a019760.
Zhao Y, Lin J, Fan Y, Lin X. Life cycle of Cryptococcus neoformans. Annu Rev Microbiol. 2019;8(73):17-42.
Francisco EC, de Jong AW, Hagen F. Cryptococcosis and Cryptococcus. Mycopathologia. 2021;186(5):729-731.
Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses. 2016;59(9):576-584.
Barcellos VA, Martins LMS, Fontes ACL, et al. Genotypic and phenotypic diversity of Cryptococcus gattii VGII clinical isolates and its impact on virulence. Front Microbiol. 2018;6(9):132.
Harris J, Lockhart S, Chiller T Cryptococcus gattii: where do we go from here? Med Mycol. 2012;50(2):113-129.
Harris JR, Lockhart SR, Sondermeyer G, et al. Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg Infect Dis. 2013;19(10):1620-1626.
Byrnes EJ, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, Heitman J. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis. 2009;199(7):1081-1086.
Clancey SA, Ciccone EJ, Coelho MA, et al. Cryptococcus deuterogattii VGIIa infection associated with travel to the pacific northwest outbreak region in an anti-aranulocyte-macrophage colony-stimulating factor autoantibody-positive patient in the United States. MBio. 2019;10(1):e02733-18.
Firacative C, Roe CC, Malik R, et al. MLST and whole-genome-based population analysis of Cryptococcus gattii VGIII links clinical, veterinary and environmental strains, and reveals divergent serotype specific sub-populations and distant ancestors. PLoS Negl Trop Dis. 2016;10(8):e0004861.
Vélez N, Escandón P. Multilocus sequence typing (MLST) of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in six departments of Colombia reveals high genetic diversity. Rev Soc Bras Med Trop. 2020;11(53):e20190422.
Maruyama FH, de Paula DAJ, Menezes IG, et al. Genetic diversity of the Cryptococcus gattii species complex in mato grosso state, Brazil. Mycopathologia. 2019;184(1):45-51.
Gillece JD, Schupp JM, Balajee SA, et al. Whole genome sequence analysis of Cryptococcus gattii from the Pacific Northwest reveals unexpected diversity. PLoS One. 2011;6(12):e28550.
Clinical Laboratory Standards Institute (CLSI). Reference Methods for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard. M27-A 4th edn. Clinical Laboratory Standards Institute; 2017.
Espinel-Ingroff A, Aller AI, Canton E, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56:5898-5906.
Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother. 2012;56:3107-3113.
Clinical Laboratory Standards Institute (CLSI). Epidemiological Cutoff Values for Antifungal Susceptibility Testing. Approved Standard. M59 2nd edn. Wayne PA: Clinical Laboratory Standards Institute; 2018.
Kassi FK, Drakulovski P, Bellet V, et al. Molecular epidemiology reveals genetic diversity amongst 363 strains of the Cryptococcus neoformans and C gattii species complex in 61 Ivorian HIV positive patients. Mycoses. 2016;59:811-817.
Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses. 2007;50(4):277-281.
Kassi FK, Bellet V, Doumbia A, et al. First case of mixed infection with Cryptococcus deuterogattii and Cryptococcus neoformans VNI in an Ivorian HIV-positive patient. JMM Case Rep. 2016;3(4):e005037.
Meyer W, Aanensen DM, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2009;47(6):561-570.
Bellet V, Kassi FK, Krasteva D, et al. First report of cryptococcosis due to Cryptococcus gattii sensu stricto VGI in an Ivorian HIV negative patient. J Mycol Med. 2021;31(2):101113.
Hagen F, Colom MF, Swinne D, et al. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis. 2012;18(10):1618-1624.
Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA. 2004;101(49):17258-17263.
Velez N, Alvarado M, Parra-Giraldo CM, Sánchez-Quitian ZA, Escandón P, Castañeda E. Genotypic diversity is independent of pathogenicity in Colombian strains of Cryptococcus neoformans and Cryptococcus gattii in Galleria mellonella. J Fungi. 2018;4(3):82.
Schmertmann LJ, Wardman A, Setyo L, et al. Identification of the environmental source of infection for a domestic ferret with cryptococcosis. J Vet Diagn Invest. 2019;31(6):828-835.
Lin KH, Lin YP, Ho MW, Chen YC, Chung WH. Molecular epidemiology and phylogenetic analyses of environmental and clinical isolates of Cryptococcus gattii sensu lato in Taiwan. Mycoses. 2021;64(3):324-335.
Cogliati M, Desnos-Ollivier M, McCormick-Smith I, et al. Genotypes and population genetics of Cryptococcus neoformans and Cryptococcus gattii species complexes in Europe and the Mediterranean area. Fungal Genet Biol. 2019;129:16-29.
Montagna MT, De Donno A, Caggiano G, et al. Molecular characterization of Cryptococcus neoformans and Cryptococcus gattii from environmental sources and genetic comparison with clinical isolates in Apulia. Italy Environ Res. 2018;160:347-352.
Jin L, Cao JR, Xue XY, et al. Clinical and microbiological characteristics of Cryptococcus gattii isolated from 7 hospitals in China. BMC Microbiol. 2020;20(1):73.
Carriconde F, Gilgado F, Arthur I, et al. Clonality and alpha-a recombination in the Australian Cryptococcus gattii VGII population-an emerging outbreak in Australia. PLoS One. 2011;6(2):e16936.
Kaocharoen S, Ngamskulrungroj P, Firacative C, et al. Molecular epidemiology reveals genetic diversity amongst isolates of the Cryptococcus neoformans/C gattii species complex in Thailand. PLoS Negl Trop Dis. 2013;7(7):e2297.
Li Y, Zou M, Yin J, Liu Z, Lu B. Microbiological, epidemiological, and clinical characteristics of patients with cryptococcal meningitis at a tertiary hospital in China: a 6-year retrospective analysis. Front Microbiol. 2020;29(11):1837.
Hagen F, Ceresini PC, Polacheck I, et al. Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest. PLoS One. 2013;8(8):e71148.
Kassi FK, Drakulovski P, Bellet V, et al. Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: a follow up study. PLoS Negl Trop Dis. 2019;13(11):e0007812.
Bertout S, Roger F, Drakulovski P, et al. African ST173 Cryptococcus deuterogattii strains are commonly less susceptible to fluconazole: an unclear mechanism of resistance. J Glob Antimicrob Resist. 2020;21:262-269.
Pharkjaksu S, Kwon-Chung KJ, Bennett JE, Ngamskulrungroj P. Population diversity and virulence characteristics of Cryptococcus neoformans/C gattii species complexes isolated during the pre-HIV-pandemic era. PLoS Negl Trop Dis. 2020;14(10):e0008651.
Lizarazo J, Escandón P, Agudelo CI, Firacative C, Meyer W, Castañeda E. Retrospective study of the epidemiology and clinical manifestations of Cryptococcus gattii infections in Colombia from 1997-2011. PLoS Negl Trop Dis. 2014;8:e3272.
Thompson L, Porte L, Díaz V, et al. Cryptococcus bacillisporus (VGIII) meningoencephalitis acquired in Santa Cruz, Bolivia. J Fungi. 2021;7(1):55.
Silva C, Juan-Sallés C, Mendes J, et al. Cryptococcus bacillisporus causing cryptococcoma of the beak of an African grey parrot (Psittacus erithacus), Portugal. Med Mycol Case Rep. 2021;3(34):8-12.
Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, IberoAmerican Cryptococcal Study Group. Molecular typing of Ibero American Cryptococcus neoformans isolates. Emerg Infect Dis. 2003;9:189-195.
Cogliati M. Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types. Scientifica. 2013;2013:675213.
Litvinseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-saharan Africa. J Infect Dis. 2005;192:888-892. pmid:16088839.
Nyazika TK, Hagen F, Meis JF, Robertson VJ Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. J Infect. 2016;72(6):745-752.
Berejnoi A, Taverna CG, Mazza M, et al. First case report of cryptococcosis due to Cryptococcus decagattii in a pediatric patient in Argentina. Rev Soc Bras Med Trop. 2019;28(52):e20180419.
Springer DJ, Billmyre RB, Filler EE, et al. Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal. PLoS Pathog. 2014;10(8):e1004285.
Farrer RA, Chang M, Davis MJ, et al. A new lineage of Cryptococcus gattii (VGV) discovered in the Central Zambezian Miombo Woodlands. MBio. 2019;10(6):e02306-19.
Coelho C, Farrer RA. Pathogen and host genetics underpinning cryptococcal disease. Adv Genet. 2020;105:1-66.